A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept

Table 1

Characteristics of all studies included in the meta-analysis.

Authors	Year	Country	Study design	(eyes)	Inclusion/exclusion criteria	Matching/comparable; factors	Study quality (points scoring scale)
Kumar [24]	2013	USA	Retro	34	IRF, SRF, or sub-RPE with adjacent IRF/SRF on OCT	BCVA, CRT	Selection: 2; Comparability: 2; Stats:1; Outcome: 6; Overall:11
Bakall [25]	2013	USA	Retro	36	CNV confirmed by OCT and FFA at baseline visit; IRF/SRF present at least for 3 months prior to conversion and treated with 3 monthly anti-VEGF injections	BCVA, CRT	Selection: 3; Comparability: 3; Stats: 1; Outcome: 4; Overall: 11
Gharbiya [26]	2014	Italy	Retro	31	IRF/SRF on OCT; At least 6 previous anti-VEGF injections; Less than 4 weeks between last anti-VEGF treatment and conversion	BCVA, CRT	Selection: 2; Comparability: 2; Stats: 3; Outcome: 6; Overall: 13
Messenger [27]	2014	USA	Retro	109	IRF, SRF, or sub-RPE with adjacent IRF/SRF on OCT; At least 12 months of anti-VEGF treatment prior to conversion; VA > 20/400 at conversion; At least 12 months of follow-up	CRT	Selection: 2; Comparability: 3; Stats: 2; Outcome: 4; Overall: 11
Wykoff [28]	2014	USA	Prosp	46	Patients who completed the 2-year SAVE trial	BCVA,CRT	Selection: 3; Comparability: 3; Stats: 3; Outcome: 6; Overall: 15
Chang [29]	2014	Australia	Prosp	50	CNV on OCT and FFA; At least 4 anti-VEGF injections prior to conversion	BCVA	Selection: 3; Comparability: 2; Stats: 3; Outcome: 6; Overall: 14
Singh [30]	2014	USA	Prosp	26	Active CNV confirmed by FFA; BCVA between 25 and 80 ETDRS letters at baseline; At least one anti-VEGF injection within 3 months of conversion	BCVA	Selection: 3; Comparability: 2; Stats: 3; Outcome: 6; Overall: 14